《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2016年 > 3期

高尿酸血症患者血清白介素-6和转化生子因子-β1水平及应用非布司他治疗前后的变化

来自:中国糖尿病杂志  编辑:张彩香 林章梅 梁艳玲 李意 王会中 等|点击数:|2016-04-05

【摘要】  目的  观察血尿酸(SUA)与白介素-6(IL-6)、转化生长因子-β1(TGF-β1)的关系,及非布司他降SUA治疗的效果。  方法  选取高尿酸血症(HUA)男性患者110例,分为无症状HUA者(sHUA组)60例和痛风者(Gout组)50例,另选取健康对照(NC)组60名。检测血清TGF-β1、IL-6、血肌酐(Scr)、SUA、高敏C反应蛋白(hsC-RP)及血脂等生化指标,采用改良的MDRD公式计算GFR。  结果  (1)Gout组血清TGF-β1、IL-6、Scr、SUA、hsC-RP、TG、BMI及SBP均高于NC组,GFR、HDL-C低于NC组(P<0.05);Gout组IL-6和hsC-RP高于sHUA组(P<0.05);sHUA组TGF-β1、IL-6、SUA、TG、高于NC组,HDL-C低于NC组。(2)血清IL-6与SUA、TGF-β1呈正相关(r=0.466、0.360,P=0.000、0.001);TGF-β1与SUA呈正相关(r=0.266,P=0.014)。(3)经非布司他降SUA治疗后,TGF-β1、IL-6、SUA下降(P=0.000)。  结论  HUA人群合并微炎状态,且促纤维化炎症因子TGF-β1升高;非布司他降SUA效果好,可有效减轻HUA引起的炎症反应。

【关键词】  高尿酸血症;白介素-6;转化生子因子-β1;非布司他

Study on the level of serum IL-6、TGF-β1 in hyperuricemic patients and after febuxostat treatment  ZHANG Cai-xiang, LIN Zhang-mei, LIANG Yan-ling, et al. Graduate College of Southern Medical University, Guangzhou 510515, China

Corresponding author: ZHU Kai-si, E-mail:zhukaisi@sina.com

Abstract】  Objective  To investigate the relationship of IL-6,TGF-β1 and uric acid in hyperuricemic patients and the effect of febuxostat in lowering uric acid.  Methods  A total of 110 male cases of hyperuricemia (HUA) were divided into symptomless hyperuricemia group(sHUA, n=60)and gout group (gout, n=50). 60 healthy volunteers served as normal controls (NC group). TGF-β1, IL-6, Scr, SUA and hsC-RP were detected in all subjects. GFR was calculated by formula of MDRD.  Results  (1)The serum TGF-β1,IL-6,Scr,SUA,hsC-RP,TG,BMI and SBP in Gout group were higher, and GFR,HDL-C were lower than those in NC group(P<0.05); IL-6 and hsC-RP in Gout group were higher than those in sHUA group; TGF-β1, IL-6, SUA, TG in sHUA group were higher. HDL-C were lower than those in NC group.(2)The correlation analysis showed that serum IL-6 was positively correlated with Src,SUA and TGF-β1(r=0.466, 0.360, P=0.000, 0.001); serum TGF-β1 was positively correlated with SUA(r=0.266, P=0.014).(3) The levels of TGF-β1,IL-6 and SUA notably decreased after febuxostat treatment(P=0.000).  Conclusion  Hyperuricemic patients presented with micro-inflammatory and higher level of stimulate fibrosis factor TGF-β1. Febuxostat treatment can effectively reduce the level of  uric acid and inhibit the corresponding inflammation.

【Key  words】  Hyperuricemia; Interleukin-6(IL-6); Transforming grouth factor-β1 (TGF-β1); Febuxostat

上一篇:不同空腹血糖水平的糖尿病患者尿酸排泄分数的变化及其相关因素分析 下一篇:糖尿病冠心病患者心肌细胞中磷脂酰基转移酶1水平的变化及影响因素分析

相关阅读

    暂时没有相关文章